Q1 2026 revenue of 36.7 billion KRW (up 36% YoY from 27.0 billion), operating profit of 13.1 billion, net profit of 11.7 billion.
Total equity of 132.8 billion, cash and equivalents of 22.9 billion, net cash position (net debt of -40.3 billion).
FY2025 dividend of 50 won per share (up 150% from 20 won), approved cancellation of 12,950 treasury shares (0.02%).
Stem cell therapy Cellgram-LC in phase 3 for liver cirrhosis, Cellgram-ED in phase 2 for erectile dysfunction, Cellgram-CKD phase 1 completed for chronic kidney disease.
Biochemical segment revenue of 36.0 billion (98% of total) driving growth, solid financial structure.